Bone disease and HIV infection

Clinical Infectious Diseases

Volumn 42, Issue 1, 2006, Pages 108-114

  Amorosa, Valerianna ^a   Tebas, Pablo ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALENDRONIC ACID; AMPRENAVIR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; EFAVIRENZ; GROWTH HORMONE RELEASING FACTOR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RALOXIFENE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STAVUDINE; TENOFOVIR; VITAMIN D;

BONE DEMINERALIZATION; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE TURNOVER; CUSHING SYNDROME; DRUG EFFICACY; DRUG SAFETY; FRAGILITY FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LONGITUDINAL STUDY; MENOPAUSAL SYNDROME; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADULT; ANTI-RETROVIRAL AGENTS; BONE DISEASES; BONE DISEASES, METABOLIC; CHILD; FEMALE; HIV INFECTIONS; HUMANS; MALE; OSTEOPOROSIS; PREVALENCE;

EID: 29244465093     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498511     Document Type: Review

References (60)

1. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63-7.
2. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001; 15:703-9.
3. Moore AL, Vashisht A, Sabin CA, et al. Reduced bone mineral density in HIV-positive individuals. AIDS 2001; 15:1731-3.
4. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15:1275-80.
5. Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001; 15:975-82.
6. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 2003; 46: 221-7.
7. Landonio S, Quirino T, Bonfanti P, et al. Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART. Biomed Pharmacother 2004; 58:505-8.
8. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in HIV-infected individuals. Clin Infect Dis 2003; 36:482-90.
9. Brown TT, Ruppe MD, Kassner R, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004; 89:1200-6.
10. Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004; 19:402-9.
11. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17:1917-23.
12. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004; 48:39-48.
13. Serrano S, Marinoso M, Soriano J, et al. Bone remodelling in human immunodeficiency virus-1-infected patients: a histomorphometric study. Bone 1995; 16:185-91.
14. Aukrust P, Haug C, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999; 84:145-50.
15. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341:72-5.
16. Ross PD, Davis JW, Epstein RS, Wasnich RD. Preexisting fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114:919-23.
17. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16:581-9.
18. Cooper OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 2003; 37(Suppl 2):S132-6.
19. Pedrazzoni M, Vescovi PP, Maninetti L, et al. Effects of chronic heroine abuse on bone and mineral metabolism. Acta Endocrinol (Copenh) 1993; 129:42-5.
20. Jacobson D, Huang J, Shevitz A, Knox T, Gorbach S, Spiegelman D. Duration of ART and change in bone mineral density over time [abstract 825]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
21. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. T, Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12:989-95.
22. Martin K, Lawson-Ayayi S, Miremont-Salame G, et al. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002). Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. HIV Med 2004; 5:421-6.
23. McComsey G, Huang J, Woolley I, et al. Fragility fractures in HIV-infected subjects, an area for improvement [abstract 743]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
24. Stephens EA, Das R, Madge S, et al. Symptomatic osteoporosis in two young HIV-positive African women. AIDS 1999; 13:2605-6.
25. Hernandez Quero J, Ortego Centeno N, Muñoz Torre M, Martinez Perez MA, Torres-Puchol JM. Alterations in bone turnover in HIV-positive patients. Infection 1993; 21:220-2.
26. Paton NIJ, Macallan D, Griffin GE, Pazianas M. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 1997; 61:30-2.
27. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. 903 Study Group. JAMA 2004; 292: 191-201.
28. Powderly W, Cohen C, Gallant J, Lu B, Enejosa J, Cheng A. Similar incidence of osteopenia and osteoporosis in ART-naive patients treated with tenofovir DF or stavudine in combination with lamivudine and efavirenz over 144 weeks [abstract 823]. 903 Study Group. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
29. Looker AC, Wahner H, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporo Int 1998; 8:468-89.
30. Dube MP, Qian D, Edmondson-Melancon H, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002; 35:475-81.
31. Tebas P, Zhang J, Yarasheski K, et al. Switch to a protease inhibitor-containing/nucleoside reverse-transcriptase inhibitor-sparing regimen increases appendicular fat and serum lipid levels without affecting glucose metabolism or bone mineral density: the results of a prospective randomized trial, ACTG 5125s [abstract 40]. Adult AIDS Clinical Trials Group. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
32. Tebas P, Yarasheski K, Henry K, et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004; 20:589-94.
33. Hazra R, Gafni R, Maldarelli F, et al. Safety, tolerability, and clinical responses to tenofovir DF in combination with other antiretrovirals in heavily treatment-experienced HIV-infected children: data through 48 weeks [abstract 928]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
34. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2(phosphonomethoxy)propyl] adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48:1469-87.
35. Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 2004; 19:714-21.
36. Fakruddin M, Yin M, Laurence J. Pathophysiologic correlates of RANKL deregulation in HIV infection and its therapy [abstract 822]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
37. Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90:4394-8.
38. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001; 15:1823-9.
39. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 2003; 278:48,251-8.
40. Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005; 150:67-78.
41. Wang MW, Wei S, Teitelbaum SL, Ross FP. The HIV protease inhibitor indinavir uniquely inhibits bone formation (abstract). J Bone Miner Res 2001; 16(Suppl):S372.
42. Wang MWH, Teitelbaum SJ, Tebas P, Powderly WG, Ross FP. Indinavir administration leads to bone loss in mice [abstract 713]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
43. Wang MW, Wei S, Faccio R, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004; 114:206-13.
44. Jain RG, Lenhard J. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 2002; 277:19247-50.
45. Pan G, Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM. AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses 2004; 20:608-20.
46. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003; 17:513-20.
47. Huang JS, Wilkie S, Sullivan MP, Grinspoon S. Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metab 2001; 86:3533-9.
48. Dolan SE, Huang J, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS 2004; 18: 475-83.
49. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 2005; 16:1345-52.
50. Arpadi SM, Horlick M, Thornton J, Cuff PA, Wang J, Kotler DP. Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr 2002; 29:450-4.
51. Rojo Conejo P, Ramos Amador JT, Garcia Pinar L, et al. Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy [in Spanish]. An Pediatr (Barc) 2004; 60:249-53.
52. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Vigano A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004; 89:24-8.
53. Seibel M. Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 2003; 32:83-113.
54. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115:282-90.
55. Hittinger G, Poggi C, Delbeke E, Profizi N, Lafeuillade A. Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients. Infection 1998; 26:100-3.
56. Mondy K, Powderly W, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005; 38:426-31.
57. Negredo E, Martinez-Lopez E, Paredes R, et al. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 2005; 19: 343-5.
58. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004; 5:269-77.
59. Fairfield WP, Treat M, Rosenthal DI, et al. Effects of testosterone and exercise on muscle leanness in eugonadal men with AIDS wasting. J Appl Physiol 2001; 90:2166-71.
60. Koutkia P, Canavan B, Breau J, Grinspoon S. Effects of growth hormone-releasing hormone on bone turnover in HIV-infected men with fat accumulation. J Clin Endocrinol Metab 2005; 90:2154-60.